Pila Pharma AB (publ) reported earnings results for the fourth quarter and full year ended December 31, 2022. For the fourth quarter, the company reported sales was SEK 0.413 million compared to SEK 0.719 million a year ago. Net loss was SEK 4.02 million compared to SEK 5.42 million a year ago. Basic loss per share from continuing operations was SEK 0.23 compared to SEK 0.34 a year ago. Diluted loss per share from continuing operations was SEK 0.23 compared to SEK 0.34 a year ago.
For the full year, sales was SEK 1.88 million compared to SEK 0.719 million a year ago. Net loss was SEK 26.78 million compared to SEK 17.21 million a year ago. Basic loss per share from continuing operations was SEK 1.55 compared to SEK 1.32 a year ago. Diluted loss per share from continuing operations was SEK 1.55 compared to SEK 1.32 a year ago.